Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value.
Publication
, Journal Article
Mark, DB; Richman, I; Hlatky, MA
Published in: JAMA Cardiol
October 1, 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
October 1, 2017
Volume
2
Issue
10
Start / End Page
1066 / 1068
Location
United States
Related Subject Headings
- Subtilisins
- Proprotein Convertases
- Humans
- Cost-Benefit Analysis
- Cholesterol, LDL
- Cardiovascular Diseases
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Mark, D. B., Richman, I., & Hlatky, M. A. (2017). Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. JAMA Cardiol, 2(10), 1066–1068. https://doi.org/10.1001/jamacardio.2017.2911
Mark, Daniel B., Ilana Richman, and Mark A. Hlatky. “Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value.” JAMA Cardiol 2, no. 10 (October 1, 2017): 1066–68. https://doi.org/10.1001/jamacardio.2017.2911.
Mark DB, Richman I, Hlatky MA. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. JAMA Cardiol. 2017 Oct 1;2(10):1066–8.
Mark, Daniel B., et al. “Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value.” JAMA Cardiol, vol. 2, no. 10, Oct. 2017, pp. 1066–68. Pubmed, doi:10.1001/jamacardio.2017.2911.
Mark DB, Richman I, Hlatky MA. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value. JAMA Cardiol. 2017 Oct 1;2(10):1066–1068.
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
October 1, 2017
Volume
2
Issue
10
Start / End Page
1066 / 1068
Location
United States
Related Subject Headings
- Subtilisins
- Proprotein Convertases
- Humans
- Cost-Benefit Analysis
- Cholesterol, LDL
- Cardiovascular Diseases
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- 3201 Cardiovascular medicine and haematology